KRAS Mutation Comparison of Testing Methods and Tissue Sampling Techniques in Colon Cancer

被引:97
作者
Franklin, Wilbur A. [1 ]
Haney, Jerry [1 ]
Sugita, Michio [1 ]
Bemis, Lynne [2 ]
Jimeno, Antonio [2 ]
Messersmith, Wells A. [2 ]
机构
[1] Univ Colorado Denver, Dept Pathol, Aurora, CO 80045 USA
[2] Univ Colorado Denver, Dept Med Oncol, Aurora, CO 80045 USA
关键词
RESOLUTION MELTING ANALYSIS; CELL LUNG-CANCER; METASTATIC COLORECTAL-CANCER; GROWTH-FACTOR RECEPTOR; K-RAS MUTATIONS; POINT MUTATION; AMPLIFICATION; CHEMOTHERAPY; ERLOTINIB; CETUXIMAB;
D O I
10.2353/jmoldx.2010.080131
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Treatment of colon carcinoma with the anti-epidermal growth factor receptor antibody Cetuximab is reported to be ineffective in KRAS-mutant tumors. Mutation testing techniques have therefore become an urgent concern. We have compared three methods for detecting KRAS mutations in 59 cases of colon carcinoma: 1) high resolution melting, 2) the amplification refractory mutation system using a bifunctional self-probing primer (ARMS/Scorpion, ARMS/S), and 3) direct sequencing. We also evaluated the effects of the methods of sectioning and coring of paraffin blocks to obtain tumor DNA on assay sensitivity and specificity. The most sensitive and specific combination of block sampling and mutational analysis was ARMS/S performed on DNA derived from 1-mm paraffin cores. This combination of tissue sampling and testing method detected KRAS mutations in 46% of colon tumors. Four samples were positive by ARMS/S, but initially negative by direct sequencing. Cloned DNA samples were retested by direct sequencing, and in all four cases KRAS mutations were identified in the DNA. in six cases, high resolution melting abnormalities could not be confirmed as specific mutations either by ARMS/S or direct sequencing. We conclude that coring of the paraffin blocks and testing by ARMS/S is a sensitive, specific, and efficient method for KRAS testing. (J Mol Diagn 2010, 12:43-50; DOI: 10.2353/jmoldx.2010.080131)
引用
收藏
页码:43 / 50
页数:8
相关论文
共 27 条
[11]   Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma [J].
Marks, Jenifer L. ;
Broderick, Stephen ;
Zhou, Qin ;
Chitale, Dhananjay ;
Li, Allan R. ;
Zakowski, Maureen F. ;
Kris, Mark G. ;
Rusch, Valerie W. ;
Azzoli, Christopher G. ;
Seshan, Venkatraman E. ;
Ladanyi, Marc ;
Pao, William .
JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (02) :111-116
[12]   Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib [J].
Miller, Vincent A. ;
Riely, Gregory J. ;
Zakowski, Maureen F. ;
Li, Allan R. ;
Patel, Jyoti D. ;
Heelan, Robert T. ;
Kris, Mark G. ;
Sandler, Alan B. ;
Carbone, David P. ;
Tsao, Anne ;
Herbst, Roy S. ;
Heller, Glenn ;
Ladanyi, Marc ;
Pao, William ;
Johnson, David H. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (09) :1472-1478
[13]   ANALYSIS OF ANY POINT MUTATION IN DNA - THE AMPLIFICATION REFRACTORY MUTATION SYSTEM (ARMS) [J].
NEWTON, CR ;
GRAHAM, A ;
HEPTINSTALL, LE ;
POWELL, SJ ;
SUMMERS, C ;
KALSHEKER, N ;
SMITH, JC ;
MARKHAM, AF .
NUCLEIC ACIDS RESEARCH, 1989, 17 (07) :2503-2516
[14]  
Nollau P, 1997, CLIN CHEM, V43, P1114
[15]   KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib [J].
Pao, W ;
Wang, TY ;
Riely, GJ ;
Miller, VA ;
Pan, QL ;
Ladanyi, M ;
Zakowski, MF ;
Heelan, RT ;
Kris, MG ;
Varmus, HE .
PLOS MEDICINE, 2005, 2 (01) :57-61
[16]  
Ruiz MIG, 2007, CELL ONCOL, V29, P257
[17]   TRANSFORMING GENES OF CARCINOMAS AND NEUROBLASTOMAS INTRODUCED INTO MOUSE FIBROBLASTS [J].
SHIH, C ;
PADHY, LC ;
MURRAY, M ;
WEINBERG, RA .
NATURE, 1981, 290 (5803) :261-264
[18]   High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer [J].
Simi, Lisa ;
Pratesi, Nicola ;
Vignoli, Marina ;
Sestini, Roberta ;
Cianchi, Fabio ;
Valanzano, Rosa ;
Nobili, Stefania ;
Mini, Enrico ;
Pazzagli, Mario ;
Orlando, Claudio .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2008, 130 (02) :247-253
[19]  
SLEBOS RJC, 1989, EUR RESPIR J, V2, P461
[20]   KRAS CODON-12 MUTATIONS OCCUR VERY FREQUENTLY IN PANCREATIC ADENOCARCINOMAS [J].
SMIT, VTHBM ;
BOOT, AJM ;
SMITS, AMM ;
FLEUREN, GJ ;
CORNELISSE, CJ ;
BOS, JL .
NUCLEIC ACIDS RESEARCH, 1988, 16 (16) :7773-7782